TORONTO, Sept. 20 /CNW/ - Fralex Therapeutics Inc. (TSX:FXI) ("Fralex" or
the "Company"), a medical technology company, today announced CE marking of
its PRIMA system. The Model 801 PRIMA device is a portable, non-invasive,
non-drug option for the treatment of chronic musculoskeletal pain in adults.
It is a Class IIa medical device in the European Union.
Completion of the European conformity assessment process for medical
devices - commonly referred to as "CE marking" - confirms the Company's
fulfillment of applicable European Union requirements and allows Fralex to
market the PRIMA device for the treatment of chronic musculoskeletal pain
within the EU.
